Literature DB >> 7882384

Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum.

M V Croce1, M R Price, A Segal-Eiras.   

Abstract

The aim of this study was to examine tissue from patients with breast carcinoma or benign breast disease for the presence of monoclonal-antibody-defined antigens, including the MUC1 mucin and carcinoembryonic antigen CEA. The tests were performed by sodium dodecyl sulphate/polyacrylamide gel electrophoretic separation of proteins, electrophoretic transfer to nitrocellulose membranes and immunostaining with the monoclonal antibodies. Some of the antigens identified are known to circulate at high levels in some but not necessarily all, breast carcinoma patients. Serum from a panel of ten breast cancer patients was subjected to a fractionation procedure designed to release antigen from immune complexes, and again these samples were analysed for the presence of monoclonal-antibody-defined antigens. A high frequency of positive reactions was detected by the anti-MUC1 monoclonal antibody C595 with both breast carcinoma subcellular membrane fractions as well as antigen fractions eluted from circulating immune complexes. No reactions were observed with equivalent materials from benign breast disease samples. The findings illustrate the variability in antigen expression between breast tumours. The data also indicate that a proportion of patients respond to their tumour by the production of antibodies that recognise the MUC1 antigen in their circulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882384     DOI: 10.1007/bf01520296

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  35 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

Authors:  K R Jerome; D L Barnd; K M Bendt; C M Boyer; J Taylor-Papadimitriou; I F McKenzie; R C Bast; O J Finn
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

3.  Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer.

Authors:  T Narita; H Funahashi; Y Satoh; T Watanabe; J Sakamoto; H Takagi
Journal:  Cancer       Date:  1993-05-15       Impact factor: 6.860

4.  Circulating immune complexes (CIC) as tumor marker in the follow-up of breast cancer.

Authors:  B Neri; T Comparini; S Ciatto; L Cataliotti; V Distante; S Bartalucci
Journal:  Cancer Detect Prev       Date:  1985

5.  Immune complexes in breast cancer patients as detected by C1q binding.

Authors:  L D Papsidero; T Nemoto; M C Snyderman; T M Chu
Journal:  Cancer       Date:  1979-11       Impact factor: 6.860

6.  Tumor marker kinetics in the monitoring of breast cancer.

Authors:  D T Kiang; L J Greenberg; B J Kennedy
Journal:  Cancer       Date:  1990-01-15       Impact factor: 6.860

7.  Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer.

Authors:  R B Herberman; M Bordes; P H Lambert; H S Luthra; R A Robins; P Sizaret; A Theofilopoulos
Journal:  Int J Cancer       Date:  1981-05-15       Impact factor: 7.396

8.  Prospective assessment of the role of five tumour markers in breast cancer.

Authors:  J F Robertson; D Pearson; M R Price; C Selby; J Pearson; R W Blamey; A Howell
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Characteristics of a cell surface antigen defined by an anti-human osteogenic sarcoma monoclonal antibody.

Authors:  M R Price; D G Campbell; R A Robins; R W Baldwin
Journal:  Eur J Cancer Clin Oncol       Date:  1983-01

10.  Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator.

Authors:  I O Ellis; C P Hinton; J MacNay; C W Elston; A Robins; A A Owainati; R W Blamey; R W Baldwin; B Ferry
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-23
View more
  5 in total

1.  MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma.

Authors:  M V Croce; M E Rabassa; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Detection and isolation of MUC1 mucin from larynx squamous cell carcinoma.

Authors:  M V Croce; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  Immune Responses to the MUC1 Mucin.

Authors:  Graeme Denton; Michael R Price
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

4.  MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis.

Authors:  Martín E Rabassa; María V Croce; Adrián Pereyra; Amada Segal-Eiras
Journal:  BMC Cancer       Date:  2006-10-25       Impact factor: 4.430

5.  Natural and Induced Humoral Responses to MUC1.

Authors:  Silvia Von Mensdorff-Pouilly; Maria Moreno; René H M Verheijen
Journal:  Cancers (Basel)       Date:  2011-07-29       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.